Lonsurf (trifluridine/tipiracil) / Otsuka 
Welcome,         Profile    Billing    Logout  
 6 Diseases   125 Trials   125 Trials   2571 News 


«12...22232425262728293031323334»
  • ||||||||||  Opdivo (nivolumab) / Ono Pharma, BMS
    Review, Journal:  Novel Agents in Heavily Pretreated Metastatic Gastric Cancer: More Shadows Than Lights. (Pubmed Central) -  Jul 31, 2019   
    Although the possible availability of active agents may be a desirable option in a very poor therapeutic scenario, clinical data from the recent studies with these drugs raise yet controversial issues. The purpose of this review is to briefly summarize the results of these novel drugs focusing on the limitations that bring some shadows on their positive therapeutic results.
  • ||||||||||  murlentamab (GM102) / Exelixis
    Enrollment closed, Enrollment change, Trial primary completion date, Combination therapy, Metastases:  Study for Evaluation of Murlentamab (GM102) Anti-tumoral Activity in Colorectal Cancers (clinicaltrials.gov) -  Jul 30, 2019   
    P2a,  N=39, Active, not recruiting, 
    The purpose of this review is to briefly summarize the results of these novel drugs focusing on the limitations that bring some shadows on their positive therapeutic results. Recruiting --> Active, not recruiting | N=30 --> 39 | Trial primary completion date: Jun 2019 --> Dec 2019
  • ||||||||||  Lonsurf (trifluridine/tipiracil) / Servier, Otsuka, TAS / 102, Stivarga (regorafenib) / Bayer
    Biomarker, Review, Journal, MSi-H Biomarker:  Third- or Later-line Therapy for Metastatic Colorectal Cancer: Reviewing Best Practice. (Pubmed Central) -  Jul 21, 2019   
    Clinical trials of emerging agents, new treatment combinations, and novel therapies continue the efforts to improve outcomes for patients with mCRC. Sharing expert opinions on best practice for treatment selection and management can ultimately improve outcomes for patients with mCRC.
  • ||||||||||  Lonsurf (trifluridine/tipiracil) / Servier, Otsuka, TAS / 102, Stivarga (regorafenib) / Bayer
    Clinical, Review, Journal:  Maximising clinical benefit with adequate patient management beyond the second line in mCRC. (Pubmed Central) -  Jun 25, 2019   
    As quality of life is an important issue for patients with mCRC, it is important to balance extended survival and the likely quality of this extended life. Likewise, discussing possible side effects along with treatment expectations with patients can greatly facilitate adherence to therapy, and ultimately improve patients' quality of life and eventual clinical outcomes.
  • ||||||||||  Lonsurf (trifluridine/tipiracil) / Otsuka
    Enrollment closed, Trial primary completion date, Metastases:  TAS-102 in Treating Advanced Biliary Tract Cancers (clinicaltrials.gov) -  Jun 7, 2019   
    P2,  N=28, Active, not recruiting, 
    Trifluridine/tipiracil could be a new treatment option in this population who represent a high unmet medical need. Suspended --> Active, not recruiting | Trial primary completion date: Sep 2020 --> Nov 2018
  • ||||||||||  Lonsurf (trifluridine/tipiracil) / Servier, Otsuka, TAS / 102, Stivarga (regorafenib) / Bayer
    Clinical, Journal, HEOR, Real-World Evidence:  Real-world treatment patterns and outcomes in refractory metastatic colorectal cancer. (Pubmed Central) -  Apr 30, 2019   
    Active 3L and beyond treatment significantly prolonged OS versus palliative care, even in selected "trial ineligible" patients. Given a high rate of palliation only care in eligible patients, improved patient access to medicine and counseling may be needed to maximize outcomes.
  • ||||||||||  Enrollment closed, Trial completion date, Trial primary completion date, Metastases:  Phase I/II Study of SGI-110 With Irinotecan Versus Regorafenib or TAS-102 in Metastatic Colorectal Cancer (clinicaltrials.gov) -  Apr 20, 2019   
    P2,  N=108, Active, not recruiting, 
    Trial completion date: May 2019 --> Jan 2020 | Trial primary completion date: May 2019 --> Jan 2020 Recruiting --> Active, not recruiting | Trial completion date: Sep 2019 --> Oct 2022 | Trial primary completion date: Sep 2019 --> Oct 2022
  • ||||||||||  Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Review, Journal, IO Biomarker:  Selecting treatment options in refractory metastatic colorectal cancer. (Pubmed Central) -  Apr 18, 2019   
    Although most therapeutic developments for mCRC in the chemorefractory setting focuses on new targets and/or more potent agents, reconsideration of established targets has gained importance with the growth of a rational pharmacogenomic approach to drug development, such as HER2. The authors describe treatment options for patients with refractory colon cancer following first- and second-line therapy.
  • ||||||||||  Avastin (bevacizumab) / Roche
    Clinical, Journal:  A Case of Complete Response to Computed Tomography-Guided Celiac Plexus Neurolysis of Pain Associated with Postoperative Recurrence of Colon Cancer (Pubmed Central) -  Apr 13, 2019   
    ...The patient was administered 5 cycles of postoperative adjuvant chemotherapy with oral tegafur/uracil(UFT)in combination with calcium folinate(UZEL)...The patient was given 8 cycles of adjuvant chemotherapy with capecitabine and oxaliplatin(CapeOX)...Multiple perineal disseminations were found intraoperatively, and chemotherapy was initiated with irinotecan plus tegafur/gimeracil/oteracil(S-1)plus bevacizumab(IRIS/BV)for the recurrent and unresectable disease...Treatment with trifluridine/tipiracil(TAS102)was started in September 2017...Since the patient did not require any rescue medication during daytime on some days, the reduction of the base opioid dose was significantly effective in improving the patient's quality of life(QOL). In patients with pain possibly caused by metastasis to the para-aortic nodes, this local therapy technique may be considered.
  • ||||||||||  Lonsurf (trifluridine/tipiracil) / Otsuka
    Enrollment closed, Trial primary completion date, PD(L)-1 Biomarker, IO biomarker:  LUPIN: Study of S 95005 in Combination With Oxaliplatin in Metastatic Colorectal Cancer (clinicaltrials.gov) -  Apr 10, 2019   
    P1,  N=94, Active, not recruiting, 
    Low skeletal muscle mass is a negative factor for survival outcomes in mCRC patients treated with salvage-line chemotherapy. Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2019 --> Aug 2019
  • ||||||||||  Lonsurf (trifluridine/tipiracil) / Servier, Otsuka
    Journal, HEOR:  Cost-effectiveness of Trifluridine/tipiracil for Previously Treated Metastatic Colorectal Cancer in England and Wales. (Pubmed Central) -  Apr 3, 2019   
    The results show that trifluridine/tipiracil is more clinically and cost-effective than regorafenib, with clinical outcomes greatly exceeding those for patients treated with BSC alone. Based on the results of the analysis, trifluridine/tipiracil offers an important new treatment option for patients with mCRC maintaining good performance status at the end of life.